You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

diabetes, ER stress, glucagon-like peptide-1 analogs

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Sexual Functioning Trial in Basel (Dulaglutide, Placebo)

Recruiting
  • Sexual Functioning
  • Basel, Switzerland
    University Hospital Basel, Endocrinology, Diabetes and Metabolis
Mar 3, 2022

Effects of Glucagon-like-Peptide-1 Analogues on Sexuality

Recruiting
  • Sexual Desire
    • Basel, Switzerland
      University Hospital Basel, Endocrinology, Diabetes and Metabolis
    Nov 28, 2022

    Glucagon-like Peptide 1 Receptor Agonists and Mental Health

    Not yet recruiting
    • Diabetes Mellitus
    • +2 more
    • GLP-1 receptor agonist
    • (no location specified)
    Aug 4, 2022

    Type1 Diabetes Trial in Baltimore (Glucagon-like peptide-1, Placebos)

    Recruiting
    • Type1 Diabetes Mellitus
    • Glucagon-like peptide-1
    • Placebos
    • Baltimore, Maryland
      University of Maryland
    Apr 8, 2022

    Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes Trial in Al Ain (GIP/GLP-1a)

    Not yet recruiting
    • Non-Alcoholic Fatty Liver Disease
    • +3 more
    • Al Ain, Abu Dhabi, United Arab Emirates
      Internal Medicine, College of Medicine and Health Sciences
    Mar 1, 2023

    GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Type 2

    Recruiting
    • Diabetes Mellitus, Type 2
    • Myocardial Infarction
    • PCI
    • Naples, Italy
      Celestino Sardu
    Aug 31, 2023

    A Pan-European Post-Authorisation Safety Study: Risk of

    Not yet recruiting
    • Pancreatic Cancer
    • Exenatide
    • Non-GLP-1 RA based glucose lowering drugs
    • (no location specified)
    Dec 21, 2022

    Type 2 Diabetes in Obese Trial in Derby (Semaglutide Pen Injector [Ozempic], Very-low Calorie Diet)

    Recruiting
    • Type 2 Diabetes Mellitus in Obese
    • Semaglutide Pen Injector [Ozempic]
    • Very-low Calorie Diet
    • Derby, United Kingdom
      University of Nottingham, Royal Derby Hospital Centre
    Oct 31, 2022

    Type 2 Diabetes, Obesity Trial in Cambridge (0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by

    Recruiting
    • Type 2 Diabetes
    • Obesity
    • 0.9% Sodium-chloride
    • +3 more
    • Cambridge, Cambridgeshire, United Kingdom
      Cambridge University Hospitals NHS Foundation Trust and The Univ
    Jan 18, 2022

    Retrospective Data of Glucagon-like Peptide-1 Participanta With

    Recruiting
    • Diabetes Mellitus, Type 2
    • Skopje, North Macedonia
      Novo Nordisk Investigational Site
    Jul 22, 2022

    Effects of GLP-1 Agonists on Gastric Volume

    Not yet recruiting
    • Diabetes
    • +3 more
    • Gastric Ultrasound
    • Charleston, South Carolina
      Medical University of South Carolina
    May 10, 2023

    Empagliflozin in Type 2 Diabetes Population With and Without

    Not yet recruiting
    • Diabetes Mellitus, Type 2
    • Durham, North Carolina
      Duke Clinical Research Institute
    Aug 8, 2022

    Type 2 Diabetes, PreDiabetes Trial in Johor Bahru (Sitagliptin)

    Completed
    • Type 2 Diabetes Mellitus
    • PreDiabetes
    • Johor Bahru, Johor, Malaysia
      Hospital Sultan Ismail
    Mar 13, 2022

    Diabetes, Diabetic Kidney Disease Trial in Sha Tin (Dulaglutide, Insulin Degludec, Continuous glucose monitor)

    Recruiting
    • Diabetes Mellitus
    • Diabetic Kidney Disease
    • Sha Tin, Hong Kong
      Prince of Wales Hospital
    Nov 8, 2022

    s and Activity Data in Type 2 Diabetes on Different Treatments

    Not yet recruiting
    • Diabetes Mellitus, Type 2
    • Lifestyle
    • +4 more
    • (no location specified)
    Sep 16, 2022

    Glucagon-Like Peptide-1 Receptor, Metformin, Obesity, Abdominal Trial in Shanghai (Liraglutide, Semaglutide, Metformin)

    Recruiting
    • Glucagon-Like Peptide-1 Receptor
    • +7 more
    • Shanghai, Shanghai, China
      Ren Ji Hospital, Shanghai Jiao Tong University School of Medicin
    Mar 9, 2023

    Severe Obesity, Type 2 Diabetes in Obese Trial in São Paulo (Analyze basal expression incretin for immunolabeling and mRNA

    Recruiting
    • Severe Obesity
    • Type 2 Diabetes Mellitus in Obese
    • Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.
    • São Paulo, Brazil
      Hospital das Clinicas da Faculdade de Medicina da USP
    Jul 7, 2022

    Type2 Diabetes Trial in Hvidovre (Entresto, Sitagliptin, Valsartan)

    Completed
    • Type2 Diabetes
    • Hvidovre, RegionH, Denmark
      Hvidovre Hospital
    May 4, 2021

    Second-line Therapies for Type 2 Diabetes and Moderate

    Enrolling by invitation
    • Type 2 Diabetes
    • Cardiac Disease
    • Glucagon like peptide 1 receptor agonist
    • +3 more
    • Rochester, Minnesota
      Mayo Clinic Rochester
    Jan 26, 2022

    Obesity, Liver Diseases, Liver Fibrosis Trial in Boston (ESG, GLP1-RA)

    Not yet recruiting
    • Obesity
    • +16 more
    • Boston, Massachusetts
      Brigham and Women's Hospital
    Nov 14, 2023

    Type 2 Diabetes Trial in Bronx (glucagon like peptide-1, glucose control)

    Completed
    • Type 2 Diabetes
    • glucagon like peptide-1
    • glucose control
    • Bronx, New York
      Albert Einstein College of Medicinie
    Apr 21, 2021

    Type 2 Diabetes, Coronary Artery Disease Trial in Athens (Liraglutide, Metformin)

    Completed
    Has Results
    • Type 2 Diabetes Mellitus
    • Coronary Artery Disease
    • Athens, Attiki, Greece
      ''Attikon'' University General Hospital
    Mar 3, 2021

    Diabetes, Diabetes, Type 2 Trial in Nijmegen (111In-DTPA-exendin-4, IRDye800CW-exendin-4)

    Unknown status
    • Diabetes Mellitus
    • Diabetes Mellitus, Type 2
    • Nijmegen, Gelderland, Netherlands
      Radboud University Medical Center
    Jan 28, 2021

    Type 2 Diabetes, Obesity Trial in Turku (Roux-en-Y, GIP-infusion, GLP-1)

    Completed
    • Type 2 Diabetes
    • Obesity
    • Roux-en-Y
    • +4 more
    • Turku, Finland
      Turku univercity hospital, PET center
    Oct 12, 2021